Mr. Kiselak has served as a member of Jade s board of directors since the completion of the Merger in April 2025 and served on Pre-Merger Jade s board of directors since July 2024. Mr. Kiselak is a Founding Partner at Fairmount Funds Management LLC, a healthcare investment firm he co-founded in April 2016. Prior to Fairmount, Mr. Kiselak was a managing director at RA Capital Management, LLC, a healthcare and life science investment firm. Mr. Kiselak currently serves as the chairman of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) and as a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), Spyre Therapeutics, Inc. (Nasdaq: SYRE) and Zenas BioPharma, Inc. (Nasdaq: ZBIO). Mr. Kiselak also serves as a director for several private companies. He previously served as a director of Dianthus Therapeutics, Inc. (Nasdaq: DNTH) from 2023 to 2025. Mr. Kiselak s extensive experience as an investor in the healthcare and life sciences industries and as a director of a number of life sciences companies contributed to our board of directors conclusion that he should serve as a director of our Company. Education Mr. Kiselak received a B.S. in Neuroscience and Economics from Amherst College.